80.30 +0.06 (0.07%)
After hours: 7:43PM EDT
|Bid||79.91 x 300|
|Ask||80.35 x 100|
|Day's range||79.56 - 80.71|
|52-week range||63.76 - 86.27|
|PE ratio (TTM)||8.72|
|Earnings date||26 Oct 2017|
|Dividend & yield||2.08 (2.56%)|
|1y target est||84.20|
Of the 28 analysts tracking Gilead Sciences in October 2017, three have recommended a “strong buy,” while 11 have recommended a “buy."
Gilead Sciences, Inc. (Nasdaq: GILD) announced today the promotion of Alessandro Riva, MD, to Executive Vice President, Oncology Therapeutics, with responsibility for Gilead’s hematology and oncology programs, including cell therapy research and development. Dr. Riva will become a member of Gilead’s senior leadership team. Dr. Riva joined Gilead in January 2017 as Senior Vice President, Hematology and Oncology Therapeutic Area Head.
Gilead Sciences, Inc. announced today the promotion of Alessandro Riva, MD, to Executive Vice President, Oncology Therapeutics, with responsibility for Gilead’s hematology and oncology programs, including cell therapy research and development.
Credit Suisse Overall, we think most U.S. biotech companies look to be in-line-to-above consensus estimates. Where we have conviction and are focused into quarter: We think Biogen (BIIB) has potential to beat based mostly on Spinraza U.S. trends after reviewing a recent slide deck from the CureSMA website.
The Zacks Analyst Blog Highlights: NIKE, Cisco Systems, Gilead Sciences, Las Vegas Sands and Aon
Cancer. Alzheimer’s. MS. Treatments from the fast-growing U.S. biotech industry provide new hope for patients. What are the top biotech companies in innovation?
Gilead Sciences, Inc. today announced the second round of recipients of its HIV cure grants program. This new commitment will provide $7.5 million to support five additional HIV cure research initiatives led by top academic institutions and focused on translational research and efficacy studies in preclinical models.
FOSTER CITY, Calif.--(BUSINESSWIRE)-- - New Funds to Support Projects in HIV Cure Discovery - Gilead Sciences, Inc. (NASDAQ:GILD) today announced the second round of recipients of its HIV cure grants program. ...
Gilead's new Kite Pharma unit is a leader in cutting-edge CAR-T therapy that fights cancer by rebuilding a patient's cells. Here's how its treatment stands out and who it helps.
Nimbus Therapeutics, which struck a $1.2 billion deal to sell a drug program focused on liver diseases to Gilead Sciences Inc. last year, has formed a new immunology collaboration with Celgene Corp.
Looking for some investments in the healthcare sector that aren't priced at a high premium? Allergan, Gilead Sciences, and DaVita are an excellent place to start.
Bigwigs of late have been investing a substantial portion of their R&D sources for the treatment of Non-Alcoholic Steatohepatitis (NASH).
Gilead Sciences, Inc. announced today that its third quarter 2017 financial results will be released on Thursday, October 26, after the market closes. At 4:30 p.m. Eastern Time, Gilead’s management will host a conference call to discuss the company’s financial results for the third quarter 2017 and provide a general business update.
The Trump Administration threw its support behind a public-private partnership with 11 drug companies to advance a new class of drugs that uses the body's immune system to fight cancer. The five-year collaboration ...
AbbVie's yield is higher than those of its peers, but expiring patents on the company's top-selling drug does make it a bit riskier than other dividend payers in healthcare.